Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymph Node Excision | 6 | 2024 | 1267 | 1.180 |
Why?
|
Lymphedema | 4 | 2022 | 526 | 1.090 |
Why?
|
Breast Neoplasms | 21 | 2024 | 21178 | 1.030 |
Why?
|
Mastectomy, Segmental | 4 | 2024 | 974 | 0.900 |
Why?
|
Axilla | 6 | 2024 | 622 | 0.830 |
Why?
|
Mastectomy, Subcutaneous | 3 | 2024 | 56 | 0.790 |
Why?
|
Sentinel Lymph Node Biopsy | 5 | 2024 | 734 | 0.670 |
Why?
|
Antibiotic Prophylaxis | 1 | 2024 | 640 | 0.640 |
Why?
|
Mastectomy | 6 | 2024 | 1861 | 0.510 |
Why?
|
Surgical Wound Infection | 1 | 2024 | 1547 | 0.480 |
Why?
|
Microsurgery | 1 | 2019 | 798 | 0.450 |
Why?
|
Neoadjuvant Therapy | 2 | 2024 | 2902 | 0.450 |
Why?
|
Nipples | 2 | 2024 | 227 | 0.400 |
Why?
|
Mammaplasty | 1 | 2020 | 1268 | 0.340 |
Why?
|
Lymph Nodes | 2 | 2024 | 3468 | 0.270 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7469 | 0.250 |
Why?
|
Neoplasm, Residual | 3 | 2024 | 1012 | 0.220 |
Why?
|
Cephalosporins | 1 | 2024 | 200 | 0.210 |
Why?
|
Gallbladder Diseases | 1 | 2003 | 139 | 0.200 |
Why?
|
Transducers | 1 | 2023 | 238 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9410 | 0.190 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2003 | 236 | 0.190 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 3 | 2024 | 934 | 0.190 |
Why?
|
Spectrum Analysis | 1 | 2022 | 443 | 0.170 |
Why?
|
Breast | 2 | 2020 | 1972 | 0.160 |
Why?
|
Quality of Life | 2 | 2020 | 13485 | 0.160 |
Why?
|
Esthetics | 1 | 2020 | 328 | 0.150 |
Why?
|
Lymphatic Metastasis | 3 | 2024 | 2900 | 0.150 |
Why?
|
Lead | 1 | 2023 | 882 | 0.140 |
Why?
|
Postoperative Complications | 1 | 2019 | 15824 | 0.140 |
Why?
|
Breast Implants | 1 | 2020 | 414 | 0.130 |
Why?
|
Paresis | 2 | 2007 | 177 | 0.130 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2016 | 208 | 0.130 |
Why?
|
Female | 21 | 2024 | 396660 | 0.120 |
Why?
|
Insulin-Like Growth Factor Binding Protein 5 | 1 | 2014 | 28 | 0.110 |
Why?
|
Hospitals, Special | 1 | 2014 | 89 | 0.110 |
Why?
|
Prognosis | 7 | 2024 | 29963 | 0.110 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2021 | 3552 | 0.100 |
Why?
|
Societies, Medical | 1 | 2024 | 3964 | 0.100 |
Why?
|
Cosmetic Techniques | 1 | 2014 | 149 | 0.100 |
Why?
|
Wound Healing | 2 | 2019 | 2800 | 0.100 |
Why?
|
Survival Rate | 3 | 2024 | 12823 | 0.090 |
Why?
|
Surgical Flaps | 1 | 2020 | 1680 | 0.090 |
Why?
|
Spinal Neoplasms | 2 | 2007 | 714 | 0.090 |
Why?
|
Adult | 11 | 2024 | 223317 | 0.090 |
Why?
|
Telomere | 1 | 2016 | 943 | 0.090 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2024 | 1097 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2024 | 39317 | 0.080 |
Why?
|
Disease-Free Survival | 1 | 2020 | 6844 | 0.080 |
Why?
|
Humans | 20 | 2024 | 767040 | 0.080 |
Why?
|
Turkey | 3 | 2016 | 256 | 0.080 |
Why?
|
Retrospective Studies | 5 | 2024 | 81659 | 0.070 |
Why?
|
Patient Selection | 1 | 2020 | 4256 | 0.070 |
Why?
|
Vitamin D | 1 | 2021 | 3312 | 0.070 |
Why?
|
Patient Satisfaction | 1 | 2020 | 3488 | 0.070 |
Why?
|
Aged | 9 | 2024 | 171319 | 0.070 |
Why?
|
Middle Aged | 11 | 2024 | 223233 | 0.070 |
Why?
|
Treatment Outcome | 3 | 2021 | 65295 | 0.060 |
Why?
|
Neoplasm Staging | 4 | 2024 | 11217 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 11872 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2014 | 2883 | 0.060 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2007 | 617 | 0.050 |
Why?
|
Gallbladder | 1 | 2003 | 308 | 0.050 |
Why?
|
Neoplasm Invasiveness | 2 | 2024 | 3611 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8048 | 0.050 |
Why?
|
Paclitaxel | 1 | 2007 | 1728 | 0.040 |
Why?
|
Cohort Studies | 2 | 2019 | 41718 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2024 | 1788 | 0.040 |
Why?
|
Risk Reduction Behavior | 1 | 2024 | 1119 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2014 | 8628 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2024 | 59548 | 0.030 |
Why?
|
Rats, Inbred F344 | 2 | 2007 | 820 | 0.030 |
Why?
|
Drug Delivery Systems | 1 | 2007 | 2212 | 0.030 |
Why?
|
Survival Analysis | 3 | 2016 | 10092 | 0.030 |
Why?
|
Neoplasm Transplantation | 2 | 2007 | 2012 | 0.030 |
Why?
|
Young Adult | 1 | 2020 | 59980 | 0.030 |
Why?
|
Restriction Mapping | 1 | 2014 | 848 | 0.030 |
Why?
|
Frozen Sections | 1 | 2014 | 153 | 0.030 |
Why?
|
Medical Oncology | 1 | 2024 | 2341 | 0.020 |
Why?
|
Ultrasonography | 1 | 2023 | 6000 | 0.020 |
Why?
|
Carcinoma, Lobular | 1 | 2013 | 480 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 904 | 0.020 |
Why?
|
Mutation | 1 | 2014 | 30211 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2014 | 1615 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2014 | 2850 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 15424 | 0.020 |
Why?
|
Hospitals, University | 1 | 2009 | 570 | 0.020 |
Why?
|
Injections, Intralesional | 1 | 2007 | 280 | 0.020 |
Why?
|
Male | 1 | 2024 | 364203 | 0.020 |
Why?
|
Risk Factors | 3 | 2024 | 74886 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54886 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 6215 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2014 | 6067 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2014 | 2744 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2014 | 22254 | 0.010 |
Why?
|
Abortion, Spontaneous | 1 | 2009 | 534 | 0.010 |
Why?
|
Reoperation | 1 | 2013 | 4325 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6513 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4780 | 0.010 |
Why?
|
Estrogen Replacement Therapy | 1 | 2009 | 1209 | 0.010 |
Why?
|
DNA Methylation | 1 | 2016 | 4426 | 0.010 |
Why?
|
Rats | 2 | 2007 | 23713 | 0.010 |
Why?
|
Cell Line, Tumor | 2 | 2007 | 17097 | 0.010 |
Why?
|
Breast Feeding | 1 | 2009 | 1362 | 0.010 |
Why?
|
Polymers | 1 | 2007 | 1624 | 0.010 |
Why?
|
Adenocarcinoma | 2 | 2007 | 6360 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2014 | 3236 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12536 | 0.010 |
Why?
|
Registries | 1 | 2013 | 8351 | 0.010 |
Why?
|
Odds Ratio | 1 | 2009 | 9660 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13646 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2007 | 10748 | 0.010 |
Why?
|
Logistic Models | 1 | 2009 | 13284 | 0.010 |
Why?
|
Risk Assessment | 1 | 2014 | 24299 | 0.010 |
Why?
|
Age Factors | 1 | 2009 | 18401 | 0.010 |
Why?
|
Smoking | 1 | 2009 | 9081 | 0.010 |
Why?
|
Body Mass Index | 1 | 2009 | 13048 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2007 | 18330 | 0.000 |
Why?
|
Animals | 2 | 2007 | 168965 | 0.000 |
Why?
|
Concepts
(119)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(5)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_